Incyte, Novartis launch drug study to treat coronavirus complication
Incyte Corp. said Friday it and Novartis AG started a late-stage clinical trial to study a drug meant to treat a serious complication of COVID-19. The biotech company said it was testing the drug Jakafi to treat COVID-19 associated cytokine storm, where the immune system overreacts to the viral infection resulting in complications like pneumonia or acute respiratory distress syndrome. Incyte said it will study the application in the U.S., while Novartis will study the drug outside the U.S. The study plans to enroll about 400 patients globally.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.